×
Artelo Biosciences Total Assets 2016-2024 | ARTL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Artelo Biosciences total assets from 2016 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
View More
Artelo Biosciences Total Assets 2016-2024 | ARTL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Artelo Biosciences total assets from 2016 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$155.8B
Bristol Myers Squibb (BMY)
$118.1B
Vertex Pharmaceuticals (VRTX)
$116B
Gilead Sciences (GILD)
$111.9B
CSL (CSLLY)
$86.5B
Regeneron Pharmaceuticals (REGN)
$81.8B
GSK (GSK)
$69.8B
Argenex SE (ARGX)
$35.7B
Alnylam Pharmaceuticals (ALNY)
$31.8B
BioNTech SE (BNTX)
$25.9B
Biogen (BIIB)
$23B
Illumina (ILMN)
$21.7B
BeiGene (BGNE)
$18.9B
Moderna (MRNA)
$14.7B
Incyte (INCY)
$13.6B
Genmab (GMAB)
$13.5B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$12.1B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$11B
Sarepta Therapeutics (SRPT)
$10.6B
Exelixis (EXEL)
$9.9B
Exact Sciences (EXAS)
$9.8B
QIAGEN (QGEN)
$9.7B
Revolution Medicines (RVMD)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.4B
Intra-Cellular Therapies (ITCI)
$9.1B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$7.9B
Ascendis Pharma (ASND)
$7.4B